Seres Therapeutics (MCRB) Cut to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a buy rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other analysts also recently issued reports about the company. Seaport Global Securities reiterated a buy rating and set a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. Cowen reiterated a buy rating on shares of Seres Therapeutics in a report on Monday, October 2nd. CIBC started coverage on Seres Therapeutics in a report on Friday, October 13th. They set an outperform rating and a $19.00 price target for the company. Oppenheimer started coverage on Seres Therapeutics in a report on Thursday, October 12th. They set an outperform rating and a $19.00 price target for the company. Finally, Citigroup started coverage on Seres Therapeutics in a research note on Thursday, October 12th. They issued a positive rating and a $19.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. Seres Therapeutics presently has a consensus rating of Buy and an average target price of $18.00.

Shares of Seres Therapeutics (NASDAQ MCRB) opened at $10.61 on Wednesday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The firm had revenue of $23.00 million during the quarter, compared to the consensus estimate of $17.29 million. During the same period last year, the business posted ($0.46) EPS. The business’s revenue was up 76.9% compared to the same quarter last year. analysts anticipate that Seres Therapeutics will post -2.33 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Seres Therapeutics by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after buying an additional 19,363 shares during the period. Ark Investment Management LLC grew its stake in shares of Seres Therapeutics by 21.5% in the 2nd quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Seres Therapeutics by 39.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after buying an additional 106,479 shares during the period. State Street Corp grew its stake in shares of Seres Therapeutics by 12.0% in the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after buying an additional 34,393 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Seres Therapeutics by 16.2% in the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after buying an additional 32,875 shares during the period. Institutional investors own 75.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Seres Therapeutics (MCRB) Cut to Hold at Zacks Investment Research” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/06/seres-therapeutics-mcrb-cut-to-hold-at-zacks-investment-research.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit